- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:35 | UK re-investigates Pfizer's eye-popping price gouging on an epilepsy drug | ||
| 13:35 | A small vaccine developer favored by the UK government in Covid-19 touts a PhIII first in chikungunya | ||
| 10:35 | Bayer nabs star biotech Vividion with a $2B buyout and an 'arms-length' pact, pulling a partner out of the IPO conga line | ||
| 10:35 | Science pioneer, pharma research chief, global health advocate and biotech entrepreneur Tadataka 'Tachi' Yamada has died | ||
| Mi | Zymergen's sudden implosion shocked biopharma. A lingering loan could make things even worse | ||
| Mi | HHS extends Aduhelm investigation into the accelerated approval pathway, wading into a brewing controversy | ||
| Mi | Shares of BeyondSpring skyrocket on new, positive cancer drug trial results | ||
| Mi | Pfizer puts the pressure on Eli Lilly's JAK inhibitor Olumiant with new data in alopecia areata | ||
| Mi | Amgen adds new NC plant to the list as part of $1B manufacturing expansion plans stateside | ||
| Mi | Amgen may see $3B+ in additional taxes; EQRx, AbCellera ink antibody development deal | ||
| Mi | Biogen, Eisai are pushing for another accelerated Alzheimer's OK - this time for BAN2401 | ||
| Mi | SoftBank claims $5B stake in Roche amid grand plans to invest in biotech - reports | ||
| Mi | Samantha Du's Zai Lab inks surprising research collab with Schrödinger for DNA damage drug | ||
| Mi | Covid-19 roundup: Early fall approval date of Pfizer-BioNTech jab still anticipated; EU buys 200m doses of Novavax vaccine | ||
| Mi | FDA slaps back small-cap's bid to repurpose 50-year-old chemotherapy | ||
| Mi | Jeff Bluestone just raised $265M to develop curative cell therapies. We asked him how | ||
| Mi | Ardelyx chops a third of its staff after stock-crushing failure in chronic kidney disease | ||
| Mi | Amgen halts a PhI for FLT3 BiTE while resuming dosing on another | ||
| Di | Synbio unicorn Zymergen jettisons founding CEO, cuts guidance as customers report lead product doesn't work | ||
| Di | Roche's PD-L1 franchise player nabs priority review; World's first psychedelics research institute opens in Australia | ||
| Di | Fast-growing BeiGene blueprints 42-acre R&D and manufacturing campus in the US, with plans to hire 'hundreds' | ||
| Di | Eli Lilly: As donanemab filing approaches, execs 'even more confident' in data package | ||
| Di | Sage drops a pair of late-stage tests for Biogen-partnered depression drug, raising the stakes on a final trial | ||
| Di | Opinion: Pricing info with new drug approvals: Time for transparency | ||
| Di | J&J, GV back a new single-cell approach for tackling inflammatory diseases and hacking the tumor microenvironment |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
